Myeloproliferative Disorder Drugs Market Analysis by Therapeutic Area (Ph+ Chronic myelogenous leukaemia (CML), Ph- Myeloproliferative Neoplasms (MPNs)) and by Region - Forecast to 2026

Request Sample Page

The global myeloproliferative disorder drugs market is estimated to be USD 8,741.4 million in 2021 and is expected to witness a CAGR of 3.81% during the forecast period. Growing research and development activities in the fields of myeloproliferative disorder drugs and technological advancements for improving patient results are driving the global market. However, the side effects of the novel drugs due to inadequate research and stringency of regulatory procedures related to production and use of these drugs are hindering the market growth.

Global Myeloproliferative Disorder Drugs Market Size (USD Million), 2021-2029

Source: Erevna Healthcare

By Therapeutic Area

Based on therapeutic area, the market is segmented into Ph+ Chronic myelogenous leukaemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs). In 2021, the Ph- Myeloproliferative Neoplasms (MPNs) segment accounted for the significant share owing to increasing number of patients and technological advancements. This segment is anticipated to grow at a significant CAGR during the forecast period owing to continuous investments by the government.

Regional Insights

North America dominated the global market in 2021 and is expected to maintain its dominance during the forecast period. Multiple product launches by major players, growing adoption of new therapeutics, and presence of a large target population are the major drivers for the growth in this region.  Asia Pacific segment is estimated to grow at a fastest CAGR during the forecast period owing to the presence of a large population, rising prevalence of myeloproliferative disorders, rising awareness, and developing healthcare infrastructure in this region.

Competitor Insights

Some of the major companies in the market are Novartis AG (Switzerland); Bristol-Myers Squibb Company (U.S.); Pfizer Inc. (U.S.); Takeda Pharmaceutical Company Ltd. (Japan); Incyte Corporation. (U.S.); Teva Pharmaceutical Industries Ltd (Israel). Investment in R&D, novel product launches, investment in R&D and strategic collaborations & M&A are some of the major strategies adopted by the leading players operating in the industry.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The myeloproliferative disorder drugs market report is categorized into the following segments and subsegments:

Myeloproliferative Disorder Drugs Market, By Type (Revenue, 2021-2029, USD Million)

  • Ph- Myeloproliferative Neoplasms (MPNs)
    • Polycythaemia Vera (PV)
    • Myelofibrosis (MF)
    • Essential thrombocythemia (ET)
  • Ph+ Chronic myelogenous leukaemia (CML)

Myeloproliferative Disorder Drugs Market, By Region (Revenue, 2021-2029, USD Million)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Scope of Myeloproliferative Disorder Drugs Market Report:

Key Parameters Details
Base Year
  • 2021
Forecast Period
  • 2022-2029
Study Coverage
  • Global and regional market size and revenue forecast
  • Segment market size and revenue forecast at global, regional, and country level
  • Competitive landscape (company share analysis, company profiles, recent development, competitive map analysis)
  • Conclusion and recommendations
Qualitative Analysis
  • Market drivers
  • Market restraints
  • Market opportunities
  • Recent market trends
  • Market challenges
  • Porter’s Five Forces analysis
  • PEST analysis
  • Value-chain analysis
  • COVID-19 impact analysis
Regional Market Scope
  • North America (U.S. and Canada)
  • Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
  • MEA (South Africa, GCC, Rest of MEA)
Company Profiles
  • Exhaustive profiles of top 15 players
  • 50+ other major players listing
15% Free Customization Available
  • You can customize the study scope to meet your exact requirement. Click here for more details

Table of Contents: Myeloproliferative Disorder Drugs Market 2021-2029

  1. Research Methodology
    1. Study Objectives
    2. Study Scope
    3. Research Assumptions
    4. Research Framework
      1. Research Models
        1. Bottom-up Approach
        2. Top-down Approach
        3. Data Triangulation
      2. Data Procurement
        1. Internal Database
        2. Secondary Research
        3. Purchased Database
        4. Primary Research
      3. Data Analysis
        1. Data Validation
        2. Market Size Estimation
        3. Market Forecast Model
      4. Quality Assessment
  1. Introduction: Myeloproliferative Disorder Drugs
  2. Executive Summary
    1. Global Market Scenario
    2. Segment Market Scenario
    3. Geographic Market Scenario
    4. COVID-19 Impact
    5. Competitive Landscape
  3. Market Dynamics
    1. Market Drivers
      1. Driver 1
      2. Driver 2
      3. Driver 3
      4. Driver 4
      5. Driver 5
    2. Market Restraint
      1. Restraint 1
      2. Restraint 2
      3. Restraint 3
      4. Restraint 4
    3. Market Opportunities
      1. Opportunity 1
      2. Opportunity 2
      3. Opportunity 3
      4. Opportunity 4
    4. Market Trends
      1. Trend 1
      2. Trend 2
      3. Trend 3
      4. Trend 4
    5. Market Challenges
      1. Challenge 1
      2. Challenge 2
      3. Challenge 3
      4. Challenge 4
  1. Market Environment Analysis
    1. Porter’s 5 Forces Analysis
    2. PESTEL Analysis
    3. Value Chain Analysis
    4. SWOT Analysis
    5. Benchmark
  2. COVID-19 Impact Analysis: Myeloproliferative Disorder Drugs Market
    1. COVID-19: Overview
    2. COVID-19 Impact on the Global Market
    3. COVID-19 Impact on the Regional Markets
  3. Market Analysis by Therapeutic Area
    1. Ph- Myeloproliferative Neoplasms (MPNs)
      1. Ph- Myeloproliferative Neoplasms (MPNs) Market Forecast, 2021-2029 (USD Million)
    2. Ph+ Chronic myelogenous leukaemia (CML)
      1. Ph+ Chronic myelogenous leukaemia (CML) Market Forecast, 2021-2029 (USD Million)
  1. Regional Market Analysis
    1. Regional Market Trends
    2. Regional Market: Comparative Analysis
  2. North America Myeloproliferative Disorder Drugs Market
    1. North America Myeloproliferative Disorder Drugs Market
      1. North America Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
      2. S. Myeloproliferative Disorder Drugs Market
        1. S. Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
        2. Canada Myeloproliferative Disorder Drugs Market
          1. Canada Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
  1. Europe Myeloproliferative Disorder Drugs Market
    1. Europe Myeloproliferative Disorder Drugs Market
      1. Europe Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
      2. Germany Myeloproliferative Disorder Drugs Market
        1. Germany Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
        2. UK Myeloproliferative Disorder Drugs Market
          1. UK Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
          2. France Myeloproliferative Disorder Drugs Market
            1. France Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
            2. Spain Myeloproliferative Disorder Drugs Market
              1. Spain Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
              2. Italy Myeloproliferative Disorder Drugs Market
                1. Italy Market Size and Forecast, 2021-2029 (USD Million)
                  1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
                2. Rest of Europe Myeloproliferative Disorder Drugs Market
                  1. Rest of Europe Market Size and Forecast, 2021-2029 (USD Million)
                    1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
  1. Asia Pacific Myeloproliferative Disorder Drugs Market
    1. Asia Pacific Myeloproliferative Disorder Drugs Market
      1. Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
      2. Japan Myeloproliferative Disorder Drugs Market
        1. Japan Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
        2. China Myeloproliferative Disorder Drugs Market
          1. China Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
          2. India Myeloproliferative Disorder Drugs Market
            1. India Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
            2. South Korea Myeloproliferative Disorder Drugs Market
              1. South Korea Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
              2. Australia Myeloproliferative Disorder Drugs Market
                1. Australia Market Size and Forecast, 2021-2029 (USD Million)
              3. Rest of Asia Pacific Myeloproliferative Disorder Drugs Market
                1. Rest of Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
  1. Latin America Myeloproliferative Disorder Drugs Market
    1. Latin America Myeloproliferative Disorder Drugs Market
      1. Latin America Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
      2. Brazil Myeloproliferative Disorder Drugs Market
        1. Brazil Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
        2. Mexico Myeloproliferative Disorder Drugs Market
          1. Mexico Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
          2. Argentina Myeloproliferative Disorder Drugs Market
            1. Argentina Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
            2. Rest of Latin America Myeloproliferative Disorder Drugs Market
              1. Rest of Latin America Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
  1. MEA Myeloproliferative Disorder Drugs Market
    1. MEA Myeloproliferative Disorder Drugs Market
      1. MEA Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
      2. GCC Myeloproliferative Disorder Drugs Market
        1. GCC Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
        2. South Africa Myeloproliferative Disorder Drugs Market
          1. South Africa Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
          2. Rest of MEA Myeloproliferative Disorder Drugs Market
            1. Rest of MEA Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Therapeutic Area, 2021-2029 (USD Million)
  1. Competitor Analysis
    1. Market Share Analysis, 2021 & 2029
    2. Competitive Mapping
    3. Key Players Market Place Analysis
    4. Major Recent Developments
  2. Company Profiles
    1. Novartis AG (Switzerland)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    2. Bristol-Myers Squibb Company (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    3. Pfizer Inc. (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    4. Takeda Pharmaceutical Company Ltd. (Japan)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    5. Incyte Corporation. (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    6. Teva Pharmaceutical Industries Ltd (Israel)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    7. Impax Laboratories (US)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    8. Lundbeck (Denmark)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    9. UCB (Belgium)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    10. Valeant Pharmaceuticals (Canada)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    11.   Company 11
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    12. Company 12
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    13. Company 13
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    14. Company 14
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    15. Company 15
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Therapeutic Area Benchmarking
      5. Recent Developments
    16. Others Prominent Players

Conclusion & Recommendations

Select License Type

Buy Now

7 Reasons to Choose EHMR Reports

  • Customer’s Satisfaction

    First and foremost client’s satisfaction, which is very important for Erevna Healthcare and we are committed towards it

  • Client Report

    Customised reports

    Expert in healthcare domain and in depth insights on the report. Erevna Healthcare also customise reports as per the client’s requirement

  • Analyst Support

    Experienced team of analysts with strong background in Pharma, Life Sciences and Biotechnology

  • Assured Quality

    Each report passes through three tiers of quality check

  • Stick to the timeline

    Stick to the timeline

    Erevna Healthcare analysts stick to the timeline

  • Quick delivery

    Quick delivery of reports as per client’s request in three different forms i.e. pdf, ppt and word

  • 24x7 Supprt

    24*7 Support

    24*7 Support post delivery/dispatch of all the reports

Trending Reports